High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Ku, Bo Mi ^a   Jung, Hyun Ae ^b   Sun, Jong Mu ^b   Ko, Young Hyeh ^b   Jeong, Han Sin ^b   Son, Young Ik ^b   Baek, Chung Hwan ^b   Park, Keunchil ^b   Ahn, Myung Ju ^b  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

EGFR; ERBB2; Molecular markers; Next generation sequencing; PIK3CA; Salivary duct carcinoma

Indexed keywords

APC PROTEIN; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; K RAS PROTEIN; KRUPPEL LIKE FACTOR 5; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MYC PROTEIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN MDM2; PROTEIN P53; SCATTER FACTOR RECEPTOR; SMAD4 PROTEIN; SOMATOMEDIN C RECEPTOR; UNINDEXED DRUG;

ADULT; AGED; APC GENE; ARTICLE; ATM GENE; AURKA GENE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CCND1 GENE; CCNE1 GENE; CDK4 GENE; CDK6 GENE; CDKN1A GENE; CDKN2A GENE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; EGFR GENE; ERBB2 GENE; ERBB3 GENE; ERBB4 GENE; FBXW7 GENE; FEMALE; FGFR1 GENE; FGFR2 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE MUTATION; HIGH THROUGHPUT SEQUENCING; HISTOPATHOLOGY; HRAS GENE; HUMAN; IGF1R GENE; KIT GENE; KLF5 GENE; MALE; MDM2 GENE; MET GENE; MITF GENE; NEXT GENERATION SEQUENCING; ONCOGENE C MYC; ONCOGENE K RAS; OVERALL SURVIVAL; PALLIATIVE THERAPY; PIK3CA GENE; PTEN GENE; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SALIVARY DUCT CARCINOMA; SALIVARY GLAND CANCER; SMAD4 GENE; STK11 GENE; TNIK GENE; TP53 GENE; COHORT ANALYSIS; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; SALIVARY GLAND DUCT; SALIVARY GLAND TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; SALIVARY DUCTS; SALIVARY GLAND NEOPLASMS;

EID: 84988597056     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0299-6     Document Type: Article

References (40)

1. Laurie SA, Licitra L: Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006, 24:2673-2678.
2. Wee DT, Thomas AA, Bradley PJ: Salivary duct carcinoma: what is already known, and can we improve survival? J Laryngol Otol 2012, 126(Suppl 2):S2-S7.
3. Kleinsasser O, Klein HJ, Hubner G: Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 1968, 192:100-105.
4. Adelstein DJ, Koyfman SA, El-Naggar AK, Hanna EY: Biology and management of salivary gland cancers. Semin Radiat Oncol 2012, 22:245-253.
5. McHugh JB, Visscher DW, Barnes EL: Update on selected salivary gland neoplasms. Arch Pathol Lab Med 2009, 133:1763-1774.
6. Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD: Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996, 77:223-230.
7. Lagha A, Chraiet N, Ayadi M, Krimi S, Allani B, Rifi H, Raies H, Mezlini A: Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol 2012, 4:19.
8. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T: Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005, 103:2526-2533.
9. Kaidar-Person O, Billan S, Kuten A: Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol 2012, 29:704-706.
10. Metzker ML: Sequencing technologies-the next generation. Nat Rev Genet 2010, 11:31-46.
11. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, Kanagal-Shamanna R, Greaves WO, Medeiros LJ, Aldape KD, Luthra R: Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn 2013, 15:607-622.
12. Karachaliou N, Mayo C, Costa C, Magri I, Gimenez-Capitan A, Molina-Vila MA, Rosell R: KRAS mutations in lung cancer. Clin Lung Canc 2013, 14:205-214.
13. Liu P, Cheng H, Roberts TM, Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644.
14. Courtney KD, Corcoran RB, Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol 2010, 28:1075-1083.
15. Gymnopoulos M, Elsliger MA, Vogt PK: Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A 2007, 104:5569-5574.
16. Kato S, Iida S, Higuchi T, Ishikawa T, Takagi Y, Yasuno M, Enomoto M, Uetake H, Sugihara K: PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Canc 2007, 121:1771-1778.
17. Li SY, Rong M, Grieu F, Iacopetta B: PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006, 96:91-95.
18. Okudela K, Suzuki M, Kageyama S, Bunai T, Nagura K, Igarashi H, Takamochi K, Suzuki K, Yamada T, Niwa H, Ohashi R, Oqawa H, Mori H, Kitamura H, Kaneko T, Tsuneyoshi T, Suqimura H: PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007, 57:664-671.
19. Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santaqata D: Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Canc Res 2013, 19:480-490.
20. Qiu W, Tong GX, Turk AT, Close LG, Caruana SM, Su GH: Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma. BioMed Res Int 2014, 2014:810487.
21. Griffith CC, Seethala RR, Luvison A, Miller M, Chiosea SI: PIK3CA mutations and PTEN loss in salivary duct carcinomas. Am J Surg Pathol 2013, 37:1201-1207.
22. Suda T, Hama T, Kondo S, Yuza Y, Yoshikawa M, Urashima M, Kato T, Moriyama H: Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma. BMC Cancer 2012, 12:416.
23. Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Conde E, Tang M, Soler G, Lopez-Encuentra A, Cigudosa JC, Sanchez-Cespedes M: Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008, 214:347-356.
24. Ettl T, Baader K, Stiegler C, Muller M, Agaimy A, Zenk J, Kuhnel T, Gosau M, Zeitler K, Schwarz S, Brockhoff G: Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 2012, 106:719-726.
25. Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK: Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Canc Res 2010, 16:2266-2274.
26. Masubuchi T, Tada Y, Maruya SI, Osamura Y, Kamata SE, Miura K, Fushimi C, Takahashi H, Kawakita D, Kishimoto S, Nagao T: Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol 2014, [Epub ahead of print] PMID24553861.
27. Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS: Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 2007, 29:907-912.
28. Clauditz TS, Reiff M, Gravert L, Gnoss A, Tsourlakis MC, Munscher A, Sauter G, Bokemeyer C, Knecht R, Wilczak W: Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas. Pathology 2011, 43:459-464.
29. Arteaga CL, Engelman JA: ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014, 25:282-303.
30. Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, Weeks L, Costello R, Posner M: Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003, 39:724-727.
31. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselqa J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl JMed 2001, 344:783-792.
32. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, Costello R, Summey C, Arquette M, Langer C, Amrein PC, Posner M: HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Canc Res 2004, 10:944-946.
33. Johnson CJ, Barry MB, Vasef MA, Deyoung BR: Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Appl Immunohistochem Mol Morphol 2008, 16:54-58.
34. Falchook GS, Lippman SM, Bastida CC, Kurzrock R: Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head Neck 2014, 36:E25-E27.
35. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, Kurnit DM, Bauer JA, Bradford CR, Carey TE: EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008, 26:3128-3137.
36. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003, 21:1980-1987.
37. Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, Licitra L: Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol 2009, 45:574-578.
38. Hamakawa H, Nakashiro K, Sumida T, Shintani S, Myers JN, Takes RP, Rinaldo A, Ferlito A: Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 2008, 30:800-809.
39. Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR: A Phase II study of Gefitinib in patients with advanced salivary gland cancers. Head Neck 2014, [Epub ahead of print] PMID24585506.
40. Dahse R, Kosmehl H: Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. Br J Cancer 2008, 99:90-92.